Back to today’s briefing

Story perspectives

FDA Fast-Tracks Promising Treatments for Eye and Skin Cancers

1/22/2025

25 4

Summary

Story summary

The FDA has accelerated the journey for Nacuity Pharmaceuticals’ NPI-001, aimed at combating oxidative stress in retinitis pigmentosa. Meanwhile, Replimune's RP1 for advanced melanoma is under priority review, with a decision expected by July 22, 2025. These groundbreaking therapies shine a light on hope for patients facing daunting medical challenges.

1 of 1

Story summary

The FDA has accelerated the journey for Nacuity Pharmaceuticals’ NPI-001, aimed at combating oxidative stress in retinitis pigmentosa. Meanwhile, Replimune's RP1 for advanced melanoma is under priority review, with a decision expected by July 22, 2025. These groundbreaking therapies shine a light on hope for patients facing daunting medical challenges.